<DOC>
	<DOCNO>NCT02515877</DOCNO>
	<brief_summary>The treatment cervical tumor depend stage disease . In advanced form ( nodal / local extension vagina / parameter ) , radiotherapy associate curietherapy , play major role . Until recently association standard treatment advanced stage uterine cancer . With combination , rate local failure ( evolutionary prosecution local recurrence ) 20 50 % stage IIb 50-75 % stage III . More 50 % patient cervical cancer locally advance ( FIGO stag II / IV ) . The standard treatment , external radiotherapy follow curietherapy allows expect survival rate 5 year approximately 30-45 % . For ten year , numerous study evaluate addition concurrent chemotherapy radiotherapy cancer cervix . More 19 randomized trial publish . A meta-analysis trial undertaken assess role radiochemotherapy cancer cervix . The first meta-analysis publish Cochrane Collaborative Group , take account 4580 patient , show improvement survival , term progression free survival overall survival patient treat radio chemotherapy respectively 16 % 12 % ( p &lt; 0.0001 ) . The rate metastasis also decrease ( p &lt; 0.0001 ) . Survival rate significantly well platinum salt use ( p &lt; 0.0001 ) . However , clinical benefit chemoradiotherapy demonstrate tumor stage [ 1 , 2 ] locally advance , possibly due small number patient . The investigator previously show antiviral agent use preclinical model , CidofovirÂ® cause selective radiosensitization cell infect papillomavirus ( HPV ) . This trial propose study new concept increase radiochemotherapy efficiency : modulation expression viral oncoproteins HPV virus antiviral agent .</brief_summary>
	<brief_title>Modulation Expression Papillomavirus ( HPV ) Oncoproteins Major Radiosensitivity : Trial Combining Antiviral Agent VISTIDE Radiochemotherapy Cervical Cancers</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Cidofovir</mesh_term>
	<criteria>1 . Patients cervix cancer : Squamous cell carcinoma adenocarcinoma stage IB2 &gt; 4 cm , II , III IVA ( International Federation Gynecology Obstetrics , regardless pelvic lymph node status ( optional surgical exploration ) without paraaortic metastasis . 2 . Detection virus genome HPV positive primary tumor . 3 . General state ECOG performance status 01 . 4 . 18 &lt; / = age &lt; / = 70 year . 5 . PN &gt; 2000 / mm3 6. hemoglobin &gt; 9 g/l transfusion necessary . 7. platelet &gt; 100 000 / mm3 8 . Serum creatinine &lt; 1.5 upper limit normal . 9 . Liver function test ( SGOT , SGPT , alkaline phosphatase bilirubin ) &lt; 1.5 upper limit normal . 10 . Life expectancy &gt; 3 month . 11 . Systematic Beta HCG Dosage premenopausal woman . 12 . Informed consent sign inform patient . 13 . Proteinuria &lt; 2g / L ( 200mg / dL ) creatinine clearance &gt; / = 55 ml / min . 1 . Other histological type cervix tumor mention inclusion criterion . 2 . Search viral sequence negative HPV tumor diagnosis . 3 . History cancer basal cell carcinoma . 4 . Pretreatment radiotherapy chemotherapy . 5 . Ongoing pregnancy . 6 . History active psychiatric illness . 7 . Nephropathy whatever grade . 8 . Infection scalable . 9 . Active infection serious underlie pathology may prevent patient receive treatment ( particular hepatic cardiac ) . 10 . Inclusion another clinical trial protocol experimental molecule ( study within one month inclusion ) . 11 . Inability submit medical monitoring study geographical , social psychological .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>